Recruiting
Phase 2

LATTICE vs. Palliative Radiation

Sponsor:

Stanford University

Code:

NCT07594431

Conditions

Metastases

Metastatic Cancer

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

LATTICE Radiotherapy

Standard radiotherapy

Study Details

Brief summary:

Unblinded, randomized study of 5-fraction LATTICE radiotherapy (20 Gy with an SIB to 66.7 Gy in 5 fractions) versus moderately dose-escalated palliative radiation (25 Gy in 5 fractions)

Conditions

Metastases

Metastatic Cancer

Study ID

NCT07594431

Start date

Aug 28, 2026

Status verified date

Sep, 2026

Completion date

Aug, 2028

Anticipated

Primary completion date

Aug, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

80 patients with confirmed metastatic tumor (>2.5 cm in short axis) will be enrolled, all ≥ 12 years of age with ECOG ≤ 2. All genders and races will be included.

Inclusion Criteria:

  • Histologically, cytologically, or radiographically confirmed diagnosis of metastatic cancer
  • One to two metastases in non-brain sites that are amenable to LATTICE radiotherapy: >2.5 cm in short axis (dimension on axial imaging that is perpendicular to the longest dimension); bone metastasis can be included if the extraosseous component is >2.5 cm in short axis
  • Age ≥12
  • ECOG Performance Status 0-2
  • For patients age 12-16, Lansky Play-Performance score 50-100
  • Negative serum or urine pregnancy test within 2 weeks prior to enrollment of people of childbearing potential
  • All patients and/or their parents or legal guardians must sign a written informed consent. For any child less than 18 years of age, assent must also be obtained in addition to parental or legal guardian consent.

Exclusion criteria:

  • Prior radiation therapy to the tumor to be treated
  • Active pregnancy
  • Diseases that place the patient at high risk of radiation complications including lupus, scleroderma, Li Fraumeni syndrome
  • The tumor to be treated is from a hematologic malignancy such as lymphoma or myeloma

Study Design

Enrollment

80 participants

Anticipated

Allocation

Randomized

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: LATTICE Radiotherapy

Participants receive 5-fraction LATTICE radiotherapy delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.

active comparator: Standard Radiotherapy

Participants receive standard radiotherapy (25 Gy in 5 fractions)

Interventions

LATTICE Radiotherapy

5-fraction LATTICE radiotherapy delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.

Standard radiotherapy

Standard radiotherapy delivered to 25 Gy in 5 fractions.

Primary outcome measure

  • Percent Tumor Volume Reduction Following Radiotherapy [ Time Frame: 90 +/- 20 days following radiotherapy ]

Central Contacts and Locations

Locations

Stanford University

Recruiting

Palo Alto, California, United States, 94304

Contacts

Principal Investigator:

Michael Gensheimer, MD

More Information

Sponsor

Stanford University

Last update posted

Sep 9, 2026

Last verified

Sep, 2026

Keywords

  • LATTICE Radiotherapy
  • Palliative Radiotherapy

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Stanford University on 2026-09-09.